Technical articles
Selection Strategies for Release, Precipitation, Co-Precipitation, and Contaminant Removal Systems in Nucleic Acid Sample Pretreatment
Selection Strategies for Release, Precipitation, Co-Precipitation, and Contaminant Removal Systems in Nucleic Acid Sample Pretreatment
The key to nucleic acid sample pretreatment lies in establishing a processing route matched to the sample matrix, target nucleic acid type, and downstream application. The release system determines template accessibility, the precipitation and co-precipitation system affects recovery stability of low-abundance nucleic acids, and the contaminant removal system directly determines compatibility with amplification, library preparation, and sequencing.
Keywords: nucleic acid pretreatment; nucleic acid release; nucleic acid precipitation; co-precipitant; contaminant removal; PCR compatibility; sample matrix; template recovery
1 Technical Objectives of Nucleic Acid Sample Pretreatment
1.1 Template Accessibility
(1) Structural disruption
The first task of pretreatment is to effectively disrupt the cell membrane, nuclear membrane, viral envelope, capsid, or tissue structure so that DNA or RNA can be released from the original sample.
(2) Nucleic acid protection
After template release, loss caused by degradation, adsorption, shearing, and multi-step transfer should be minimized as much as possible, especially for low-copy samples, low-volume samples, and high-molecular-weight nucleic acid samples.
1.2 Recovery Efficiency
(1) Retention of low-abundance templates
For low-load pathogen samples, trace tissue samples, cell-free nucleic acid samples, and trace RNA samples, the pretreatment system must not only achieve release, but also maintain sufficient recovery efficiency.
(2) Need for concentration
When sample volume is large but template abundance is low, precipitation or solid-phase recovery steps are often used to increase final concentration and improve the stability of downstream analytical input.
1.3 Downstream Compatibility
(1) Amplification compatibility
Residual proteins, polysaccharides, lipids, salts, heme, bile salts, humic acids, and lysis reagents may all inhibit PCR, RT-PCR, and qPCR.
(2) Enzymatic compatibility
If downstream steps involve reverse transcription, ligation, restriction digestion, A-tailing, or library construction, the requirements for template purity and buffer background after pretreatment are usually higher than in direct-amplification workflows.
Table 1 Functional Positioning of the Four Types of Systems in Nucleic Acid Sample Pretreatment
System | Main Task | Technical Focus | Main Risk |
Release system | Lyse the sample and expose nucleic acids | Template accessibility | Incomplete lysis, nucleic acid degradation, co-release of inhibitors |
Precipitation system | Concentrate and recover nucleic acids | Template retention and concentration | Loss of low-abundance samples, salt co-precipitation |
Co-precipitation system | Improve precipitation stability of trace nucleic acids | Recovery of trace templates | Introduction of exogenous background, co-precipitation of impurities |
Contaminant removal system | Remove inhibitors and impurities | Downstream compatibility | Excessive purification leading to nucleic acid loss |
2 Selection Strategies for Release Systems
2.1 Main Types of Release Systems
(1) Mild release systems
These are usually based on mild detergents, buffer salts, and nucleic acid-protective components, with an emphasis on obtaining amplifiable templates under relatively low-damage conditions.
(2) Strong release systems
These typically incorporate stronger chaotropic salts, detergents, or protein-denaturing conditions, and are used to disrupt more complex cellular or viral structures.
(3) Enzyme-assisted release systems
These use proteases, lysozyme, chitinase, cellulase, and related enzymes to assist in breaking down sample structures, and are suitable for bacteria, fungi, plants, and cell wall-rich samples.
(4) Mechanical-chemical combined release systems
These use homogenization, grinding, bead beating, or sonication to improve lysis uniformity, and are suitable for tissues, microbial biomass, environmental particulate samples, and other systems in which purely chemical lysis is insufficient.
2.2 Release Priorities for Different Sample Types
(1) Cultured cells and suspension cells
These samples are structurally relatively simple. The critical issue is often not lysis strength, but nuclease control and downstream amplification compatibility. If the downstream application is direct PCR or qPCR, a mild release system is usually sufficient; if RNA detection is involved, RNase inactivation capacity should be prioritized.
(2) Tissue samples
The main challenges in tissue pretreatment are structural complexity, high protein background, and relatively strong local nuclease activity. Fibrotic tissues, adipose tissues, and necrotic tissues usually require stronger lysis conditions together with subsequent contaminant removal steps.
(3) Bacterial and fungal samples
The key issue in these samples is whether the cell wall is sufficiently disrupted, rather than lysis buffer strength alone. Gram-positive bacteria, spores, fungi, and yeasts are usually better handled with combined enzymatic digestion, heat lysis, and mechanical disruption.
(4) Swab and body fluid samples
These samples commonly present low template abundance, complex mucus background, and transfer loss. The release system should minimize transfer steps as much as possible while maintaining low inhibitor background and direct-amplification compatibility.
2.3 Principles for Selecting Release Systems
(1) Base selection on sample structure
Cell walls, extracellular matrix, mucus, and particulate background determine the lysis route. Release intensity should not be judged independently of sample structural features.
(2) Constrain selection by analytical use
If the released sample goes directly into amplification, system compatibility should take priority over lysis strength. If purification steps follow, lysis capacity may be increased appropriately.
(3) Take RNA protection as a prerequisite
In RNA pretreatment, release efficiency and nucleic acid protection must be considered simultaneously. Enhanced lysis should not be pursued at the expense of introducing obvious degradation risk.
3 Selection Strategies for Precipitation Systems
3.1 Functional Positioning of Precipitation Systems
(1) Nucleic acid concentration
The primary significance of precipitation is to recover and concentrate nucleic acids dispersed in a relatively large volume, thereby increasing the final concentration and facilitating entry into subsequent reactions.
(2) Buffer exchange
For lysis systems containing high salt, detergents, or components unfavorable to downstream reactions, precipitation can serve as a preliminary buffer exchange approach.
(3) Retention of low-abundance templates
In low-load samples, if concentrated recovery is not performed, released templates may remain too dilute or distributed in too large a volume to enter the detection system stably.
3.2 Differences Among Common Precipitation Systems
(1) Ethanol precipitation
This is a mature system suitable for routine DNA or RNA recovery, especially for medium- to high-abundance nucleic acid samples. However, recovery efficiency for low-concentration templates may be insufficient, so it often needs to be combined with a co-precipitation system.
(2) Isopropanol precipitation
This can achieve nucleic acid precipitation in a smaller volume and is advantageous for concentrating large-volume samples. However, it more readily co-precipitates salts and impurities, so subsequent washing requirements are higher.
(3) High-salt and alcohol combined precipitation
By adjusting ionic strength, this system improves nucleic acid precipitation efficiency and is suitable for some trace samples and special buffer backgrounds. However, if salt control is inadequate, downstream amplification and enzymatic reactions may be affected.
3.3 Principles for Selecting Precipitation Systems
(1) Prioritize precipitation for large-volume, low-abundance samples
These samples usually require precipitation for concentration; otherwise, the stability of direct amplification input is poor.
(2) Balance recovery with contaminant removal in complex lysates
If detergents, proteins, or chaotropic salts remain in the lysis system, precipitation should be combined with washing or downstream purification rather than used as the sole final treatment step.
(3) Control mechanical damage in high-molecular-weight DNA samples
Large DNA fragments are more prone to shearing during pellet resuspension, so vigorous pipetting and repeated transfers should be avoided.
4 Selection Strategies for Co-Precipitation Systems
4.1 Technical Significance of Co-Precipitation Systems
(1) Improving precipitation stability of trace nucleic acids
The main role of a co-precipitation system is not to increase total nucleic acid amount, but to reduce the risk of losing trace templates during precipitation, supernatant removal, and washing.
(2) Improving handling of low-concentration samples
When the pellet is invisible or highly unstable, co-precipitation systems improve the consistency of pellet formation and retention.
4.2 Common Co-Precipitation Strategies
(1) Glycogen-based co-precipitation
Suitable for recovery of trace DNA or RNA, and especially common in low-concentration RNA precipitation.
(2) Linear polymer-based co-precipitation
Suitable for extremely low-level nucleic acid samples and usually more helpful for low-copy recovery.
(3) Nucleic acid-based co-precipitation
This can improve precipitation efficiency, but introduces exogenous nucleic acid background, making it unsuitable for ultra-low-background quantification, absolute quantification, or high-precision sequencing pretreatment.
4.3 Principles for Selecting Co-Precipitation Systems
(1) Prioritize use in low-concentration samples
Trace RNA, cell-free DNA, viral nucleic acids, and other trace-template samples usually benefit more from co-precipitation systems.
(2) Control background in high-sensitivity analysis
If downstream applications involve digital PCR, low-copy quantification, or library construction, co-precipitation strategies with lower background interference should be preferred.
(3) Co-precipitation does not replace contaminant removal
Co-precipitation improves recovery stability, but cannot resolve co-precipitation of inhibitors.
5 Selection Strategies for Contaminant Removal Systems
5.1 Main Sources of Contamination
(1) Residual proteins and enzymes
These are common in tissue, cell, and blood samples and may directly affect polymerase, reverse transcriptase, and ligase activity.
(2) Lipids and membrane components
These are common in adipose tissue, plasma, and membrane-rich samples and may affect nucleic acid adsorption and amplification stability.
(3) Polysaccharides and secondary metabolites
These are common in plants, fungi, and some environmental samples and are major sources of PCR inhibition.
(4) Heme, bile salts, and humic acids
These are typically found in blood, gastrointestinal samples, and environmental samples, respectively, and strongly inhibit amplification systems.
5.2 Main Routes of Contaminant Removal
(1) Protein removal systems
These reduce protein background through protein denaturation, protease digestion, organic phase separation, or solid-phase adsorption, and are suitable for high-protein samples.
(2) Solid-phase purification systems
These use silica membranes or magnetic beads to retain nucleic acids while removing salts, small molecules, and some inhibitors, and are the most commonly used integrated contaminant-removal route.
(3) Inhibitor-specific removal systems
Special inhibitors in blood, feces, plant, and environmental samples require more targeted treatment rather than simple application of routine cell-sample workflows.
5.3 Principles for Balancing Contaminant Removal
(1) Template abundance determines purification intensity
High-abundance samples can tolerate more extensive purification steps, whereas low-copy samples require caution to avoid excessive purification and template loss.
(2) Downstream use determines purification grade
Direct PCR can tolerate a certain amount of background, but library construction, long-read sequencing, and highly sensitive quantification usually require a higher level of contaminant control.
Table 2 Key Treatment Priorities for Different Contaminant Backgrounds
Contaminant Type | Common Sample | Main Impact | Treatment Priority |
Protein/enzyme | Cells, tissues, blood | Inhibits enzymatic reactions, increases background | Protein removal, solid-phase purification |
Lipid | Adipose tissue, plasma | Affects adsorption and amplification compatibility | Phase separation, delipidation, downstream purification |
Polysaccharide | Plants, fungi | Inhibits PCR, increases viscosity | Polysaccharide removal, enhanced washing |
Heme | Whole blood, bloodstains | Strong PCR inhibition | Purification after release or dedicated removal |
Humic acid | Soil, environmental samples | Strong amplification inhibition | Inhibitor-specific removal |
Bile salts and complex intestinal components | Feces, digestive fluids | Affect enzyme activity and template stability | Enhanced contaminant removal combined with inhibitor-tolerant systems |
6 Pretreatment Selection Logic for Different Sample Types
6.1 Cultured Cells and Routine Laboratory Samples
These samples are structurally relatively simple. If the downstream application is routine PCR or qPCR, mild release systems are generally preferred. If template abundance is low or long-term preservation is needed, a precipitation step may be added. If the background is relatively clean, contaminant removal can be simplified appropriately.
6.2 Blood and Body Fluid Samples
The main challenge in blood samples lies in heme, protein, and salt background. If the target is rapid qualitative amplification, a release system combined with an inhibitor-tolerant amplification system may be suitable. If the target is highly sensitive quantification or low-copy detection, additional contaminant removal is usually more appropriate.
6.3 Tissue Samples
The key issues in tissue samples are structural disruption, protein removal, and preservation of nucleic acid integrity. Fibrotic tissues, adipose tissues, and necrotic tissues usually require stronger release conditions combined with more thorough contaminant control.
6.4 Bacterial, Fungal, and Colony Samples
The main issue in these samples is whether the cell wall has been sufficiently disrupted. If the purpose is only colony PCR or rapid identification, a release-plus-direct-amplification strategy may be suitable. If high-quality DNA or RNA is required, additional purification and contaminant removal steps should be included.
6.5 Plant, Fecal, and Environmental Samples
These samples are generally not suitable for processing with release reagents alone. Polysaccharides, humic acids, phenolic compounds, and complex particulate background strongly inhibit amplification, so a combined route involving release, precipitation, co-precipitation, and inhibitor-specific contaminant removal is generally more appropriate.
Table 3 Product Table Related to Nucleic Acid Sample Pretreatment
Product Type | Catalog No. | Name | Grade and Purity | Applicable Research Direction / Use |
Release/lysis | Nucleic Acid Release Reagent | BioReagent, Suitable for molecular biology, PCR Reagent | Suitable for extraction-free or rapid pretreatment workflows, especially for direct-amplification sample processing | |
Release/strong denaturing lysis | Guanidine thiocyanate | UltraBio™, Suitable for molecular biology, ≥99%(AT) | Suitable for strong denaturing lysis and nuclease inactivation, especially for RNA samples or complex sample pretreatment | |
Post-release deproteinization | Proteinase K from Tritirachium album limber | EnzymoPure™, ≥20 units/mg dry weight | Suitable for degradation of protein background after lysis, improving DNA/RNA purity and downstream amplification compatibility | |
Release/complex sample separation | CTAB Precipitation Solution | BioReagent, Suitable for molecular biology, for DNA and RNA applications | Suitable for lysis and impurity separation in pretreatment of high-polysaccharide and high-polyphenol samples | |
Co-precipitation | Carrier RNA (Poly A) | BioReagent, sterile, for DNA and RNA applications, PCR Reagent, ≥99% | Suitable for precipitation recovery of low-concentration nucleic acids or trace templates and for improving pellet stability | |
Co-precipitation | Glycogen (for nucleic acid precipitation, 5 mg/mL) | BioReagent, DNase, RNase free, Suitable for molecular biology, for DNA and RNA applications, 5.0 mg/mL | Suitable for precipitation of trace DNA/RNA, especially for recovery of low-input samples | |
Co-precipitation | Glycogen (for nucleic acid precipitation, 20 mg/mL) | BioReagent, DNase, RNase free, Suitable for molecular biology, for DNA and RNA applications, 20 mg/mL | Suitable for higher-level co-precipitation systems, especially for extremely low-input or large-volume sample concentration | |
Contaminant removal/post-purification | RNA Clean Beads | — | Suitable for post-purification of RNA samples to reduce residual salts, phenols, and small-molecule impurities | |
Contaminant removal/post-purification | UltraBio™ RNA Clean Magnetic Beads | — | Suitable for magnetic bead cleanup of RNA samples, improving compatibility with downstream RT-PCR, library preparation, and sequencing | |
Contaminant removal/post-purification | UltraBio™ Small DNA Clean Beads | BioReagent, DNase, RNase free, Suitable for molecular biology, for DNA and RNA applications | Suitable for recovery and post-purification of small DNA fragments, reducing inhibitor and low-molecular-weight impurity background | |
Integrated pretreatment/extraction | Magnetic Universal Genomic DNA Kit | BioReagent, for DNA and RNA applications | Suitable for genomic DNA pretreatment of routine samples, integrating release, contaminant removal, and recovery steps | |
Integrated pretreatment/extraction | Magnetic Blood Genomic DNA Kit | BioReagent, for DNA and RNA applications | Suitable for blood sample pretreatment, emphasizing DNA release and purification under blood-background conditions | |
Integrated pretreatment/extraction | Plant Genomic DNA Extraction Kit | BioReagent, for DNA and RNA applications | Suitable for plant sample pretreatment, especially for DNA extraction from high-polysaccharide/high-polyphenol samples | |
Integrated pretreatment/extraction | Bacteria Genomic DNA Kit | — | Suitable for bacterial sample pretreatment and genomic DNA release/recovery | |
Integrated pretreatment/extraction | Pathogenic Microbiome DNA/RNA Kit | — | Suitable for pretreatment of pathogenic microorganism samples, balancing DNA/RNA release and contaminant removal | |
Integrated pretreatment/extraction | FFPE DNA/RNA Kit | — | Suitable for pretreatment of fixed tissues, balancing DNA/RNA release and recovery | |
Integrated pretreatment/extraction | AllPure DNA/RNA/Protein Kit | — | Suitable for integrated pretreatment workflows enabling simultaneous recovery of DNA, RNA, and protein |
7 Principles for Selecting Pretreatment Workflows
7.1 Use Sample Complexity to Determine Workflow Length
The more complex the sample, the less appropriate it is to rely on a single-step pretreatment workflow. Complex samples usually require coordinated implementation of lysis, contaminant control, recovery, and, when necessary, co-precipitation.
7.2 Use Template Abundance to Determine Whether Recovery Should Be Strengthened
When template abundance is high, the workflow can be simplified appropriately. When template abundance is low, more attention should be paid to precipitation efficiency, co-precipitation strategy, and control of transfer loss.
7.3 Use Detection Purpose to Determine Purification Grade
If the downstream application is direct PCR, crude templates are often acceptable. If the downstream application is highly sensitive quantification, library construction, or long-fragment analysis, contaminant removal should be enhanced and loss of nucleic acid integrity carefully controlled.
7.4 Use RNA Stability to Determine Operating Conditions
RNA pretreatment usually places greater emphasis than DNA pretreatment on time control, low-temperature handling, and nuclease inactivation conditions. For RNA samples, the release and contaminant removal systems should not simply follow DNA-processing logic.
Table 4 Recommendations for Selecting Sample Pretreatment Routes
Sample Characteristic | More Suitable Strategy |
Simple structure, high template abundance, downstream PCR | Mild release + direct amplification |
Low template abundance, large sample volume | Release + precipitation/co-precipitation + necessary cleanup |
Complex tissues or high-protein samples | Strong release + protein removal + purified recovery |
Polysaccharide-rich or inhibitor-rich samples | Release + inhibitor-specific contaminant removal + purification |
RNA detection | Balance lysis and RNase control, with rapid purification if necessary |
In nucleic acid sample pretreatment, release, precipitation, co-precipitation, and contaminant removal jointly determine template quality and downstream reaction compatibility. Workflow design should be based on sample characteristics, template abundance, and analytical purpose, while maintaining a balance among template accessibility, recovery efficiency, and contaminant control.
For more related articles, please see below: